Table 2 Summary of patients’ clinical history
Sample ID | Smoking status | Former recurrences (treatment) and comorbidities | Pre- operative treatment | Post-operative treatment | Treatment response | Progression and time to progression | Cancer-specific death |
|---|---|---|---|---|---|---|---|
BLCa22 | Active (30 PY) | BLCa (Ta), prostatic adenocarcinoma (T2c) | No | No | N/A | No | N/A |
BLCa27 | N/A | BLCa (Ta and T1, 6x Epirubicin instillation 6 x BCG instillation), prostate and lung cancer | No | No | N/A | 210 days lymph nodes and lung mets | Yes |
BLCa33 | Former (2013) | Adenocarcinoma of the prostate (T1b) | 4x NAC cisp/gem | No | Yes | No | N/A |
BLCa34 | Former (2009, 70-80 PY) | N/A | No | 1x Epirubicin instillation | Yes | No | N/A |
BLCa35 | N/A | Incidental prostatic adenocarcinoma (T1a), hepatocellular carcinoma | No | No | N/A | No | No |
BLCa40 (BLCa35) | N/A | BLCa35 | No | No | N/A | No | No |
BLCa46 | No | N/A | No | 6x BCG instillation | Yes | No | No |
BLCa47 | N/A | N/A | No | No | N/A | No | N/A |
BLCa48 | Former (until 1990, 30 PY) | Former BLCa (Ta, 6x BCG instillation, 3x tremelimumab and durvaalumab) | No | 3x Adjuvant chemo cisp/gem | Yes | No | N/A |
BLCa50 | N/A | Prostate cancer (T2a) | No | No | N/A | No | N/A |
BLCa57 | N/A | Acinar prostatic adenocarcinoma (T2c), diagnosed with panurothelial disease (1x Epirubicin and 6x BCG instillation) | No | No | N/A | 488 days (BLCa112) | N/A |
BLCa112 (BLCa57) | N/A | BLCa57 | No | No | N/A | No | N/A |
BLCa60 | No | Former BLCa (Ta and T1), prostatic adenocarcinoma (pT2a) | No | No | N/A | No | N/A |
BLCa61 | N/A | Former BLCa (Ta and T1, 1x BCG instillation) | No | No | No | 463 days 1st relapse (uns., urethra), 793 days 2nd relapse (uns., urethra penis) | N/A |
BLCa69 | Former (2019, 40 PY) | Acute myeloid leukemia (BCR-ABL1) | No | 1x Epirubicin instillation | No | 46 days 1st relapse (uns., Ta HG, lateral left bladder wall), 197 days 2nd relapse (BLCa81) | N/A |
BLCa81 (BLCa69) | BLCa69 | BLCa69 | No | 6x BCG instillation | No | 389 days from 1st (BLCa69) 3rd relapse (uns., Ta HG, posterior bladder wall), 446 days 4th relapse (sampled, Relapse 2, atypical urothelial, posterior bladder wall) followed by epirubicin treatment, 679 days 5th relapse (uns., Ta HG, penile urethra), 699 days 6th relapse (sampled, Relapse 3, Ta HG, urethra) | N/A |
BLCa82 | Active (70 PY) | N/A | No | Palliative chemo (carbo/gem) | No | Pulmonary and hepatic mets (post-operative) | N/A |
BLCa85 | N/A | Acinary prostatic adenocarcinoma (T1a) | No | No | N/A | No | N/A |
BLCa86 (BLCa85) | N/A | BLCa85 | No | No | N/A | No | N/A |
BLCa92 | N/A | N/A | No | No | No | 314 days liver mets (palliative chemo carbo/gem) | N/A |
BLCa98 | No | Benign prostate hyperplasia | No | No | N/A | No | N/A |
BLCa100 | Active (60 PY) | Acinary prostatic adenocarcinoma (T1a), BLCa (Ta and Tis) | 4x NAC cisp/gem | No | N/A | No | N/A |
